Literature DB >> 26548546

Using 'big data' to validate claims made in the pharmaceutical approval process.

Thomas Wasser1, Kevin Haynes1, John Barron1, Mark Cziraky1.   

Abstract

Big Data in the healthcare setting refers to the storage, assimilation, and analysis of large quantities of information regarding patient care. These data can be collected and stored in a wide variety of ways including electronic medical records collected at the patient bedside, or through medical records that are coded and passed to insurance companies for reimbursement. When these data are processed it is possible to validate claims as a part of the regulatory review process regarding the anticipated performance of medications and devices. In order to analyze properly claims by manufacturers and others, there is a need to express claims in terms that are testable in a timeframe that is useful and meaningful to formulary committees. Claims for the comparative benefits and costs, including budget impact, of products and devices need to be expressed in measurable terms, ideally in the context of submission or validation protocols. Claims should be either consistent with accessible Big Data or able to support observational studies where Big Data identifies target populations. Protocols should identify, in disaggregated terms, key variables that would lead to direct or proxy validation. Once these variables are identified, Big Data can be used to query massive quantities of data in the validation process. Research can be passive or active in nature. Passive, where the data are collected retrospectively; active where the researcher is prospectively looking for indicators of co-morbid conditions, side-effects or adverse events, testing these indicators to determine if claims are within desired ranges set forth by the manufacturer. Additionally, Big Data can be used to assess the effectiveness of therapy through health insurance records. This, for example, could indicate that disease or co-morbid conditions cease to be treated. Understanding the basic strengths and weaknesses of Big Data in the claim validation process provides a glimpse of the value that this research can provide to industry. Big Data can support a research agenda that focuses on the process of claims validation to support formulary submissions as well as inputs to ongoing disease area and therapeutic class reviews.

Entities:  

Keywords:  Bias; Big data; Claims analysis; Outcomes research; Validity

Mesh:

Year:  2015        PMID: 26548546     DOI: 10.3111/13696998.2015.1108919

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  5 in total

Review 1.  Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery.

Authors:  Nicholas Ekow Thomford; Dimakatso Alice Senthebane; Arielle Rowe; Daniella Munro; Palesa Seele; Alfred Maroyi; Kevin Dzobo
Journal:  Int J Mol Sci       Date:  2018-05-25       Impact factor: 5.923

2.  Development of stroke identification algorithm for claims data using the multicenter stroke registry database.

Authors:  Jun Yup Kim; Keon-Joo Lee; Jihoon Kang; Beom Joon Kim; Moon-Ku Han; Seong-Eun Kim; Heeyoung Lee; Jong-Moo Park; Kyusik Kang; Soo Joo Lee; Jae Guk Kim; Jae-Kwan Cha; Dae-Hyun Kim; Tai Hwan Park; Moo-Seok Park; Sang-Soon Park; Kyung Bok Lee; Hong-Kyun Park; Yong-Jin Cho; Keun-Sik Hong; Kang-Ho Choi; Joon-Tae Kim; Dong-Eog Kim; Wi-Sun Ryu; Jay Chol Choi; Mi-Sun Oh; Kyung-Ho Yu; Byung-Chul Lee; Kwang-Yeol Park; Ji Sung Lee; Sujung Jang; Jae Eun Chae; Juneyoung Lee; Hee-Joon Bae
Journal:  PLoS One       Date:  2020-02-14       Impact factor: 3.240

Review 3.  Big Data in traumatic brain injury; promise and challenges.

Authors:  Denes V Agoston; Dianne Langford
Journal:  Concussion       Date:  2017-07-10

4.  Pricing through health apps generated data-Digital dividend as a game changer: Discrete choice experiment.

Authors:  Alexandra Heidel; Christian Hagist; Christian Schlereth
Journal:  PLoS One       Date:  2021-07-26       Impact factor: 3.240

5.  Structure-based screening of natural product libraries in search of potential antiviral drug-leads as first-line treatment to COVID-19 infection.

Authors:  S J Aditya Rao; Nandini P Shetty
Journal:  Microb Pathog       Date:  2022-03-22       Impact factor: 3.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.